The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia

摘要: Idelalisib is a first in class, delta isoform specific, PI3-kinase inhibitor. Based on its high level of efficacy and acceptable safety profile, this oral drug has been approved by the US Food Drug Administration as single agent for treatment relapsed or refractory small lymphocytic lymphoma, follicular non-Hodgkin combination with rituximab patients chronic leukemia. Adverse effects particular concern include diarrhea, pneumonitis, transient elevations hepatic transaminase levels. Efforts to improve activity have included combinations standard chemotherapy agents, such bendamustine, other targeted therapies, including checkpoint inhibitors. However, associated life-threatening fatal toxicities. Thus, development regimens should be conducted carefully context clinical research study. vital role second-line therapy leukemia, especially high-risk disease multiple comorbidities, studies are exploring use front-line outcome indolent B-cell malignancies.